Glutathione
Endogenous antioxidant system; Route and formulation matter
Brief Overview: Glutathione is a tripeptide antioxidant made from glutamate, cysteine, and glycine. It supports redox balance, detoxification, and cellular defense. Evidence lens: Evidence differs by route and biomarker. IV glutathione, oral reduced glutathione, liposomal products, S-acetyl glutathione, and precursors such as NAC/glycine are not interchangeable. How to read this: if you're new, avoid thinking of glutathione as a simple stimulant. Once you're past the basics, distinguish plasma glutathione, red-blood-cell glutathione, intracellular GSH/GSSG ratio, and clinical outcomes.
- Glutathione is an endogenous tripeptide composed of glutamate, cysteine, and glycine.
- Although not a therapeutic peptide in the same sense as many entries, it is included because injectable and IV glutathione are common in peptide-clinic practice.
- Glutathione is a tripeptide antioxidant, not a hormone-like peptide. Route and form matter: reduced GSH, S-acetyl-GSH, liposomal products, topical products, inhaled/nasal, and IV are not interchangeable.
It cycles between reduced (GSH) and oxidized (GSSG) forms; The GSH/GSSG ratio is the meaningful redox readout, not a single value.
- Antioxidant defense: directly scavenges reactive oxygen species and free radicals, protecting DNA, lipids, and proteins.
- Detoxification: in the liver it binds toxins, heavy metals, and pollutants (Phase II conjugation), making them water-soluble for excretion.
- Recharges other antioxidants: regenerates vitamins C and E so they stay active longer.
- Mitochondrial protection: a primary defender of the mitochondria, keeping energy production efficient.
- Melanogenesis inhibition: in skin it inhibits tyrosinase and shifts pigment from darker eumelanin toward lighter pheomelanin.
- Its biology centers on redox buffering, detoxification conjugation, mitochondrial protection, and recycling with NADPH-dependent systems. More glutathione is not always better; Redox balance matters. The mechanism here is a plausibility map, not proof of a clinical outcome.
- Bioavailability: standard oral glutathione is poorly absorbed, but liposomal and S-acetyl forms largely bypass gut degradation and raise systemic levels.
- Neuroprotection: work in Parkinson's and Alzheimer's models points to reduced neuroinflammation by limiting oxidative bursts in the brain.
- Immune support: replenishing GSH has been reported to increase natural-killer-cell cytotoxicity substantially, aiding antiviral response.
- Skin: randomized trials support systemic skin-lightening, though results depend on the length of the loading phase.
- Caveat: evidence is stronger for correcting deficiency and specific oxidative-stress contexts than for broad detox or longevity claims.
- Human evidence varies by route and indication. Oral forms can affect body stores over time, topical evidence is local/cosmetic, and IV use is common clinically but not a universal wellness fix. These are separate tiers of evidence: preclinical data, regional human reports, approved-product evidence, and community anecdotes.
Below you'll find reported clinical-label, research, and community-use dosing contexts where available. Educational reference only, not dosing instructions for you.
- Protocol 1: Wellness/Longevity - Oral Liposomal [Community/Biohacker/Anecdotal]; Route: Oral (Liposomal); Dose: 500 mg daily; Timing: Morning fast / empty stomach for liposomal and acetyl forms; Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written.
- Protocol 2: Clinical/Skin Lightening - Oral Liposomal [Clinical/Human Trial]; Route: Oral (Liposomal); Dose: 1,000 mg daily; Timing: Morning fast / empty stomach for liposomal and acetyl forms; Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written.
- Protocol 3: Wellness/Longevity - S-Acetyl-GSH [Community/Biohacker/Anecdotal]; Route: S-Acetyl-GSH; Dose: 200 mg daily; Timing: Morning fast / empty stomach for liposomal and acetyl forms; Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written.
- Protocol 4: Clinical/Skin Lightening - S-Acetyl-GSH [Clinical/Human Trial]; Route: S-Acetyl-GSH; Dose: 400 mg – 600 mg daily; Timing: Morning fast / empty stomach for liposomal and acetyl forms; Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written.
- Protocol 5: Wellness/Longevity - IV [Community/Biohacker/Anecdotal]; Route: Intravenous (IV); Dose: 600 mg weekly; Timing: Morning fast / empty stomach for liposomal and acetyl forms; Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written.
- Protocol 6: Clinical/Skin Lightening - IV [Clinical/Human Trial]; Route: Intravenous (IV); Dose: 1,200 mg – 2,400 mg weekly; Timing: Morning fast / empty stomach for liposomal and acetyl forms; Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written.
- Protocol 7: Wellness/Longevity - NAC precursor [Community/Biohacker/Anecdotal]; Route: Precursors (NAC); Dose: 600 mg twice daily; Timing: Morning fast / empty stomach for liposomal and acetyl forms; Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written.
- Protocol 8: Clinical/Skin Lightening - NAC precursor [Clinical/Human Trial]; Route: Precursors (NAC); Dose: 1,200 mg twice daily; Timing: Morning fast / empty stomach for liposomal and acetyl forms; Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written.
- Form and route matter before any amount is meaningful. NAC/glycine precursor strategies are separate from direct glutathione administration. Protocol rows are educational context, not personalized instructions, and product-label directions control when an approved product exists.
- Time until steady state: not a single calculable number.
- Half-life basis: plasma glutathione handling is short and compartmental, while intracellular pools depend on synthesis, recycling, oxidative load, and precursor availability.
- Beginner translation: If you're new, glutathione is more like a cellular redox pool than a weekly drug. Blood levels, cellular levels, and symptom changes can move differently.
- Practical interpretation: Track clinical context, oxidative-stress markers where appropriate, liver enzymes, renal function, and adverse effects instead of relying on plasma half-life.
- Comparison note: reduced glutathione, liposomal glutathione, S-acetyl glutathione, NAC, glycine, and methylation support can affect the glutathione system differently. Route and formulation determine what is being tested.
- Oral absorption and intracellular conversion are form-dependent. Plasma spikes after IV are different from sustained intracellular redox changes. PK estimates are most useful for timing and accumulation awareness, not for proving efficacy or safety.
- Common supportive pairings include NAC, glycine, selenium, vitamin C, alpha-lipoic acid, and adequate protein intake.
- These are biochemical supports, not proof that a stack treats disease.
- Avoid combining high-dose antioxidant protocols with chemotherapy or radiation without oncology approval.
- Common pairings include NAC, glycine, vitamin C, alpha-lipoic acid, NAD precursors, and mitochondrial peptides. Overlapping antioxidants can blunt adaptive training signals in some contexts. A sound stack accounts for both mechanism overlap and additive safety, tolerability, and interpretation risks.
- Generally well tolerated: high oral doses may cause mild bloating, cramping, or loose stools.
- Zinc depletion: long-term, high-dose use can lower zinc over time.
- IV risks: intravenous use carries higher risk, including allergic reactions and, rarely, liver or kidney stress at extreme unmonitored doses, so it needs sterility, rate control, and oversight.
- Asthma warning: inhaled glutathione can trigger bronchospasm in sensitive airways.
- Possible issues include bronchospasm with inhaled forms, GI upset, headache, sulfur sensitivity, and unclear effects in active chemotherapy/radiation contexts. IV quality and sterility matter. The honest safety picture covers both known risks and uncertainty risks, especially where human data are limited.
- GSH/GSSG ratio: the gold standard for redox status; A higher ratio indicates a healthier, better-protected cell.
- 8-OHdG: a urinary marker of oxidative DNA damage that a working protocol would lower.
- GGT (gamma-glutamyl transferase): elevated levels can signal trouble recycling glutathione, often tied to liver stress.
- Context tracking: liver enzymes, renal function, CBC, and asthma symptoms with nebulized use, alongside symptom response.
- Track goal-specific endpoints: oxidative-stress markers if available, liver enzymes when relevant, symptoms, skin outcomes for topical use, and respiratory tolerance for inhaled/nasal routes. Useful monitoring matches the claimed goal, the most plausible risk, and objective baseline measures.
- FDA: recognized as "Generally Recognized as Safe" for food use, but the agency has warned against injectable skin-lightening drips, which lack standardized safety data for that use.
- WADA: not a prohibited substance, but IV infusions over 100 mL per 12-hour period are banned regardless of contents unless medically necessary.
- Clinical use: widely sold as a supplement and used in hospitals (usually via the precursor NAC) as the antidote for acetaminophen poisoning.
- Availability does not prove efficacy; Athletes should check product ingredients and anti-doping rules.
- Glutathione exists in supplement, cosmetic, compounded, and clinical-use contexts. Regulatory status depends heavily on route, claims, and product category. Regulatory status spans distinct categories: FDA approval, ex-U.S. approval, investigational development, compounding review, supplement/cosmetic status, and RUO-market availability.